


## EN40

Cat. No.:	HY-122577
CAS No.:	2094547-67-6
Molecular Formula:	C <sub>13</sub> H <sub>15</sub> NO <sub>2</sub>
Molecular Weight:	217.26
Target:	Aldehyde Dehydrogenase (ALDH)
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, stored under nitrogen

\* The compound is unstable in solutions, freshly prepared is recommended.



### SOLVENT & SOLUBILITY

#### In Vitro

Ethanol : 100 mg/mL (460.28 mM; Need ultrasonic)  
 DMSO : ≥ 100 mg/mL (460.28 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	4.6028 mL	23.0139 mL	46.0278 mL
	5 mM	0.9206 mL	4.6028 mL	9.2056 mL	
	10 mM	0.4603 mL	2.3014 mL	4.6028 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

EN40 is a potent, selective aldehyde dehydrogenase 3A1 (ALDH3A1) inhibitor as a covalent ligand, exhibits an IC<sub>50</sub> value of 2 μM<sup>[1]</sup>

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 2 μM (ALDH3A1)<sup>[1]</sup>

#### In Vitro

EN40 (10-1000 μM; 48 hours) shows inhibitory effect on ALDH3A1 activity and impairs A549 cell survival<sup>[1]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.  
 Cell Viability Assay<sup>[1]</sup>

Cell Line:	A549 cells
Concentration:	10 μM; 100 μM; 1000 μM
Incubation Time:	48 hours

	Result:	Inhibited A549 cells survival.
<b>In Vivo</b>	EN40 (intraperitoneal injection; 50mg/kg; from 14 days; once per day) exerts strong anti-tumorigenic effects in established A549 tumor xenografts, shows good tolerability with no body weight loss in mice <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	SCID mice with A549 cells <sup>[1]</sup>
	Dosage:	50 mg/kg
	Administration:	Intraperitoneal injection; 50mg/kg; from 14 days; once per day
	Result:	Had strong anti-tumorigenic effects in tumor xenografts.

## REFERENCES

[1]. Counihan JL, et al. Chemoproteomics-Enabled Covalent Ligand Screening Reveals ALDH3A1 as a Lung Cancer Therapy Target. ACS Chem Biol. 2018 Aug 17;13(8):1970-1977

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA